2025
Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial
Loi S, Salgado R, Curigliano G, Romero Díaz R, Delaloge S, Rojas García C, Kok M, Saura C, Harbeck N, Mittendorf E, Yardley D, Suárez Zaizar A, Caminos F, Ungureanu A, Reinoso-Toledo J, Guarneri V, Egle D, Ades F, Pacius M, Chhibber A, Chandra R, Nathani R, Spires T, Wu J, Pusztai L, McArthur H. Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. Nature Medicine 2025, 31: 433-441. PMID: 39838118, PMCID: PMC11835735, DOI: 10.1038/s41591-024-03414-8.Peer-Reviewed Original ResearchPathological complete responseIncreased pCR ratePhase 3 trialNeoadjuvant chemotherapyBreast cancerER+/HER2- BCNivolumab armPCR rateAnti-programmed death 1 agentsDouble-blind phase 3 trialEndpoint of pathologic complete responseStromal tumor-infiltrating lymphocyte levelsProgrammed death-ligand 1 expressionEstrogen receptor-positive breast cancerLower pathologic complete responseTumor-infiltrating lymphocyte levelsRandomized phase 3 trialReceptor-positive breast cancerHigh riskLigand 1 expressionEstrogen receptor-positivePrimary breast cancerTaxane-based chemotherapyDense lymphocytic infiltrateT cell immunosurveillanceSafety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years
Armstrong A, Lebwohl M, Warren R, Sofen H, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp K, Kisa R, Vaile J, Berger V, Vritzali E, Hoyt K, Colombo M, Scotto J, Banerjee S, Strober B, Thaçi D, Blauvelt A. Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years. JAMA Dermatology 2025, 161: 56-66. PMID: 39602111, PMCID: PMC11736510, DOI: 10.1001/jamadermatol.2024.4688.Peer-Reviewed Original ResearchLong-term extension trialsExposure-adjusted incidence ratesSevere plaque psoriasisLong-term extensionModerate to severe plaque psoriasisAdverse eventsPlaque psoriasisDouble-blind phase 3 trialStatic Physician's Global Assessment scoreDiscontinuation due to adverse eventsDay 1Physician Global Assessment scoreIncidence rateEffective long-term treatmentUpper respiratory tract infectionClinical response rateGlobal assessment scorePhase 3 trialRespiratory tract infectionsWeeks of treatmentYear of treatmentLong-term treatmentAdverse cardiovascular eventsLong-term safetyCumulative period
2023
Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease
Cohen S, van Dyck C, Gee M, Doherty T, Kanekiyo M, Dhadda S, Li D, Hersch S, Irizarry M, Kramer L. Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease. The Journal Of Prevention Of Alzheimer's Disease 2023, 10: 771-777. PMID: 37874099, DOI: 10.14283/jpad.2023.123.Peer-Reviewed Original ResearchConceptsZarit Burden InterviewPhase 3 trialEarly Alzheimer's diseaseAlzheimer's diseaseQoL-ADPartner burdenMean changeDouble-blind phase 3 trialCerebrospinal fluid evidenceHumanized IgG1 monoclonal antibodyMarkers of amyloidLife-5 DimensionsHealth-related qualityPhase 3 developmentCare partner burdenLess increaseCerebral amyloid accumulationLess declineYears of ageQuality of lifePositron emission tomographyMild cognitive impairmentIgG1 monoclonal antibodyValuable patientsBurden Interview
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply